Cargando…

Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience

BACKGROUND: Commonly known as Batten disease, the neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of rare pediatric lysosomal storage disorders characterized by the intracellular accumulation of autofluorescent material (known as lipofuscin), progressive neurodegeneration...

Descripción completa

Detalles Bibliográficos
Autores principales: Badilla-Porras, R., Echeverri-McCandless, A., Weimer, J. M., Ulate-Campos, A., Soto-Rodríguez, A., Gutiérrez-Mata, A., Hernández-Con, L., Bogantes-Ledezma, S., Balmaceda-Meza, A., Brudvig, J., Sanabria-Castro, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751374/
https://www.ncbi.nlm.nih.gov/pubmed/35012600
http://dx.doi.org/10.1186/s13023-021-02162-z
_version_ 1784631665793957888
author Badilla-Porras, R.
Echeverri-McCandless, A.
Weimer, J. M.
Ulate-Campos, A.
Soto-Rodríguez, A.
Gutiérrez-Mata, A.
Hernández-Con, L.
Bogantes-Ledezma, S.
Balmaceda-Meza, A.
Brudvig, J.
Sanabria-Castro, A.
author_facet Badilla-Porras, R.
Echeverri-McCandless, A.
Weimer, J. M.
Ulate-Campos, A.
Soto-Rodríguez, A.
Gutiérrez-Mata, A.
Hernández-Con, L.
Bogantes-Ledezma, S.
Balmaceda-Meza, A.
Brudvig, J.
Sanabria-Castro, A.
author_sort Badilla-Porras, R.
collection PubMed
description BACKGROUND: Commonly known as Batten disease, the neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of rare pediatric lysosomal storage disorders characterized by the intracellular accumulation of autofluorescent material (known as lipofuscin), progressive neurodegeneration, and neurological symptoms. In 2002, a disease-causing NCL mutation in the CLN6 gene was identified (c.214G > T) in the Costa Rican population, but the frequency of this mutation among local Batten disease patients remains incompletely characterized, as do clinical and demographic attributes for this rare patient population. OBJECTIVE: To describe the main sociodemographic and clinical characteristics of patients with a clinical diagnosis for Batten Disease treated at the National Children's Hospital in Costa Rica and to characterize via molecular testing their causative mutations. METHODS: DNA extracted from buccal swabs was used for CLN6 gene sequencing. Participants’ sociodemographic and clinical characteristics were also obtained from their medical records. RESULTS: Nine patients with a clinical diagnosis of Batten disease were identified. Genetic sequencing determined the presence of the previously described Costa Rican homozygous mutation in 8 of 9 cases. One patient did not have mutations in the CLN6 gene. In all cases where the Costa Rican CLN6 mutation was present, it was accompanied by a substitution in intron 2. Patients were born in 4 of the 7 Costa Rican provinces, with an average onset of symptoms close to 4 years of age. No parental consanguinity was present in pedigrees. Initial clinical manifestations varied between patients but generally included: gait disturbances, language problems, visual impairment, seizures and psychomotor regression. Cortical and cerebellar atrophy was a constant finding when neuroimaging was performed. Seizure medication was a common element of treatment regimens. CONCLUSIONS: This investigation supports that the previously characterized c.214G > T mutation is the most common causative NCL mutation in the Costa Rican population. This mutation is geographically widespread among Costa Rican NCL patients and yields a clinical presentation similar to that observed for CLN6 NCL patients in other geographies.
format Online
Article
Text
id pubmed-8751374
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87513742022-01-12 Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience Badilla-Porras, R. Echeverri-McCandless, A. Weimer, J. M. Ulate-Campos, A. Soto-Rodríguez, A. Gutiérrez-Mata, A. Hernández-Con, L. Bogantes-Ledezma, S. Balmaceda-Meza, A. Brudvig, J. Sanabria-Castro, A. Orphanet J Rare Dis Research BACKGROUND: Commonly known as Batten disease, the neuronal ceroid lipofuscinoses (NCLs) are a genetically heterogeneous group of rare pediatric lysosomal storage disorders characterized by the intracellular accumulation of autofluorescent material (known as lipofuscin), progressive neurodegeneration, and neurological symptoms. In 2002, a disease-causing NCL mutation in the CLN6 gene was identified (c.214G > T) in the Costa Rican population, but the frequency of this mutation among local Batten disease patients remains incompletely characterized, as do clinical and demographic attributes for this rare patient population. OBJECTIVE: To describe the main sociodemographic and clinical characteristics of patients with a clinical diagnosis for Batten Disease treated at the National Children's Hospital in Costa Rica and to characterize via molecular testing their causative mutations. METHODS: DNA extracted from buccal swabs was used for CLN6 gene sequencing. Participants’ sociodemographic and clinical characteristics were also obtained from their medical records. RESULTS: Nine patients with a clinical diagnosis of Batten disease were identified. Genetic sequencing determined the presence of the previously described Costa Rican homozygous mutation in 8 of 9 cases. One patient did not have mutations in the CLN6 gene. In all cases where the Costa Rican CLN6 mutation was present, it was accompanied by a substitution in intron 2. Patients were born in 4 of the 7 Costa Rican provinces, with an average onset of symptoms close to 4 years of age. No parental consanguinity was present in pedigrees. Initial clinical manifestations varied between patients but generally included: gait disturbances, language problems, visual impairment, seizures and psychomotor regression. Cortical and cerebellar atrophy was a constant finding when neuroimaging was performed. Seizure medication was a common element of treatment regimens. CONCLUSIONS: This investigation supports that the previously characterized c.214G > T mutation is the most common causative NCL mutation in the Costa Rican population. This mutation is geographically widespread among Costa Rican NCL patients and yields a clinical presentation similar to that observed for CLN6 NCL patients in other geographies. BioMed Central 2022-01-10 /pmc/articles/PMC8751374/ /pubmed/35012600 http://dx.doi.org/10.1186/s13023-021-02162-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Badilla-Porras, R.
Echeverri-McCandless, A.
Weimer, J. M.
Ulate-Campos, A.
Soto-Rodríguez, A.
Gutiérrez-Mata, A.
Hernández-Con, L.
Bogantes-Ledezma, S.
Balmaceda-Meza, A.
Brudvig, J.
Sanabria-Castro, A.
Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience
title Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience
title_full Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience
title_fullStr Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience
title_full_unstemmed Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience
title_short Neuronal Ceroid Lipofuscinosis Type 6 (CLN6) clinical findings and molecular diagnosis: Costa Rica’s experience
title_sort neuronal ceroid lipofuscinosis type 6 (cln6) clinical findings and molecular diagnosis: costa rica’s experience
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8751374/
https://www.ncbi.nlm.nih.gov/pubmed/35012600
http://dx.doi.org/10.1186/s13023-021-02162-z
work_keys_str_mv AT badillaporrasr neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience
AT echeverrimccandlessa neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience
AT weimerjm neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience
AT ulatecamposa neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience
AT sotorodrigueza neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience
AT gutierrezmataa neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience
AT hernandezconl neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience
AT bogantesledezmas neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience
AT balmacedamezaa neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience
AT brudvigj neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience
AT sanabriacastroa neuronalceroidlipofuscinosistype6cln6clinicalfindingsandmoleculardiagnosiscostaricasexperience